PMV Pharmaceuticals, Inc. $PMVP Shares Bought by BML Capital Management LLC

BML Capital Management LLC lifted its position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report) by 37.5% during the third quarter, Holdings Channel.com reports. The firm owned 7,330,000 shares of the company’s stock after purchasing an additional 2,000,000 shares during the period. PMV Pharmaceuticals accounts for 6.5% of BML Capital Management LLC’s holdings, making the stock its 4th biggest position. BML Capital Management LLC owned approximately 0.14% of PMV Pharmaceuticals worth $12,241,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of PMVP. Eversept Partners LP acquired a new stake in PMV Pharmaceuticals in the 1st quarter valued at $2,912,000. BlackRock Inc. acquired a new position in PMV Pharmaceuticals during the second quarter worth $1,233,000. Stonepine Capital Management LLC bought a new position in shares of PMV Pharmaceuticals in the second quarter valued at $718,355. Walleye Capital LLC bought a new position in shares of PMV Pharmaceuticals in the second quarter valued at $450,000. Finally, Bank of America Corp DE bought a new position in shares of PMV Pharmaceuticals in the second quarter valued at $322,000. 90.20% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PMVP has been the subject of a number of recent research reports. Weiss Ratings raised PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Wall Street Zen downgraded shares of PMV Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of PMV Pharmaceuticals in a research report on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.33.

Check Out Our Latest Stock Report on PMV Pharmaceuticals

PMV Pharmaceuticals Trading Up 5.0%

PMV Pharmaceuticals stock opened at $1.27 on Friday. PMV Pharmaceuticals, Inc. has a 12 month low of $1.02 and a 12 month high of $1.91. The business’s 50 day simple moving average is $1.39 and its 200 day simple moving average is $1.31. The company has a market cap of $67.89 million, a price-to-earnings ratio of -0.82 and a beta of 1.52.

PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.18). As a group, equities research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.36 earnings per share for the current fiscal year.

PMV Pharmaceuticals Company Profile

(Free Report)

PMV Pharmaceuticals is a biopharmaceutical company focused on developing precision cancer treatments. Its research centers on the tumor-suppressor protein p53, which is altered in many cancers, with the goal of restoring its function through targeted medicines. The company’s lead investigational drug, rezatapopt (also known as PC14586), is designed to reactivate a specific mutated form of p53 called Y220C. PMV has studied the drug in clinical trials for patients with advanced solid tumors carrying that mutation.

Further Reading

Want to see what other hedge funds are holding PMVP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report).

Institutional Ownership by Quarter for PMV Pharmaceuticals (NASDAQ:PMVP)

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.